Edition:
United Kingdom

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

67.05USD
16 Feb 2018
Change (% chg)

$-1.05 (-1.54%)
Prev Close
$68.10
Open
$67.55
Day's High
$69.05
Day's Low
$66.25
Volume
166,179
Avg. Vol
264,915
52-wk High
$136.90
52-wk Low
$28.35

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $4,516.76
Shares Outstanding(Mil.): 37.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA

01 Feb 2018

BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel

* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN ISRAEL

30 Jan 2018

Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug

Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company's breast cancer drug, sending its shares down 30 percent.

23 Jan 2018

Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug

Jan 23 Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company's breast cancer drug, sending its shares down 30 percent.

23 Jan 2018

BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application

* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY

11 Jan 2018

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

* PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS

11 Dec 2017

BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA

* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA

22 Nov 2017

BRIEF-Puma Biotechnology reports Q3 adj. loss per share $1.36

* Puma Biotechnology reports third quarter 2017 financial results

09 Nov 2017

Earnings vs. Estimates